Alpha Tau Medical announced that their Alpha DaRT therapy achieved a 100% local disease control rate in 19 evaluable pancreatic cancer patients across two first-in-human trials. The treatment showed a favorable safety profile with only 8 mild device-related adverse events in 7 of 26 patients, mostly resolving within two weeks. This therapy, delivered via a streamlined endoscopic ultrasound procedure, is designed for patients with limited options, including those ineligible for chemotherapy or heavily pre-treated. These promising results, presented at DDW 2026, suggest Alpha DaRT could become a significant new option for treating pancreatic cancer, with ongoing trials planned to further validate its benefits.
BlackRock, Inc. has reported that its direct and indirect ownership in Orion Oyj has dropped below the 5% threshold as of June 15, 2026. This change requires a formal disclosure under Finnish securities law. The reduction in BlackRock's stake may aff...
On June 15, 2026, BlackRock, Inc. and its funds reduced their total holdings in Orion Corporation to below 5% of the company's shares and voting rights. This change was disclosed under the Finnish Securities Market Act, indicating a decrease from a p...
US stock futures showed mixed results with the S&P 500 slightly down while the Dow Jones and Nasdaq 100 edged higher following a recent rally. The market reacted to a preliminary US-Iran agreement aimed at extending a ceasefire and reopening the Stra...
MindWalk Holdings Corp. emphasizes the importance of a connected, trustworthy biological data layer over AI model size in drug discovery. The company launched ReefIQ™, a biological context layer, and LensAI™, a reasoning platform, aiming to reduce co...
Space Exploration Technologies Corp. (SpaceX) saw its shares surge over 11% in premarket trading, pushing its market capitalization close to $3 trillion, surpassing Amazon to become the fifth-largest company globally. This rapid valuation increase ha...
